Anna's Daybreak News

_{Just facts, you think for yourself}

Tuesday, 5:12 AM

April 15, 2025

Good morning news friend! Explore the stories that reveal where the world is—and where it’s headed.📰🌟

Click here to read the poll results and comments from our previous edition.

Can’t see all 6 articles in this email? Gmail sometimes crops our emails, click here to view full edition.

Iran and U.S. Nuclear Talks Round 2

The U.S. and Iran will resume nuclear talks on April 19 in Muscat, Oman. Iran’s uranium enrichment has reached 60%, near weapons-grade, prompting U.S. demands to halt the program.

President Trump has warned of military action if no deal is reached. Sanctions relief is key for Iran, whose economy remains under pressure. The April 12 talks were called constructive, but distrust lingers after the U.S. exited the 2015 deal.

Iran seeks guarantees for any new commitments. IAEA head Rafael Grossi will visit Iran to address inspection access. U.S. envoy Steve Witkoff and Iran’s Abbas Araghchi lead the delegations.

Sources: AP News, Com, Decode39, Reuters, EuroNews.

Credit Card Late Fee Regulation Overturned

The Trump administration is reversing a rule that capped credit card late fees at $8. The CFPB filed to vacate the rule, aligning with banking groups that called it unlawful.

The previous cap was $32, and the rollback could save banks $10 billion annually. U.S. District Judge Mark Pittman had blocked the rule, citing violations of the CARD Act.

Critics argued it would increase late payments and hurt credit access. The CFPB and trade groups reached a consent judgment to dismiss the case without further claims.

This move rolls back a Biden-era regulation on credit card penalty fees.

Sources: Reuters, AmericanBanker, Law360, Bloomberg.

Bank of America’ $540 Million FDIC Fine

A federal judge ordered Bank of America to pay $540.3 million to the FDIC for underpaying deposit insurance premiums from Q2 2013 to the end of 2014.

The FDIC originally sued for $1.12 billion, alleging the bank misreported risk exposure under a 2011 rule. Judge Loren AliKhan upheld the FDIC’s authority but limited the claim due to timing.

She rejected the bank’s objections and ruled that a "perfect measure" of risk isn’t required. Bank of America denied wrongdoing and said it had reserved funds for the payment.

The court barred recovery of funds owed before early 2013 due to filing delays.

Sources: Reuters, PYMNTS, Law360, Bloomberg, Investing.

Data Breach at Hertz

Hertz reported a data breach caused by vulnerabilities in Cleo Communications, its file transfer vendor, between October and December 2024.

At least 3,400 customers in Maine were affected, with data including names, contact info, credit cards, driver’s licenses, and some Social Security or passport numbers.

The Clop ransomware gang claimed responsibility. Hertz said its own systems were not breached and there’s no evidence of fraud. The company is notifying customers and responding to the incident.

Sources: Reuters, Investing, TechCrunch, Bloomberg.

Bristol Myers’ Heart Drug Fails Trial

Bristol Myers Squibb’s drug mavacamten (Camzyos) failed to meet primary endpoints in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy (nHCM).

Involving 580 patients, the ODYSSEY-HCM study showed no improvements in symptoms or functional capacity after 48 weeks. Camzyos is approved for the obstructive form of the disease.

No new safety issues were reported, but the FDA’s heart failure warning remains. The results highlight the difficulty in treating nHCM.

Sources: Reuters, BioSpace, Investing.

Non-Hallucinogenic LSD

UC Davis researchers developed JRT, a non-hallucinogenic LSD-derived drug that promotes neuroplasticity. By modifying two atoms in LSD’s structure, JRT retains therapeutic effects without psychedelic risks.

In mouse studies, it increased dendritic spine density by 46% and synapse density by 18% in the prefrontal cortex. JRT is 100 times more potent than ketamine and doesn’t trigger hallucinogenic behaviors or psychosis-related gene expression.

The drug may treat schizophrenia and other neuropsychiatric disorders. Developed over five years through a 12-step process, JRT could offer new treatment options for patients unable to tolerate conventional psychedelics.

Sources: SciTechDaily, UCDavis, GEN, NSN.

“My computer operating system is so out of date that people don’t even write viruses for it any more.”

Did you know we also write in-depth deep dives? They are long, packed with insights, and have received rave reviews. If you’re up for a detailed, action-packed read, check them out:

• The End of the Easy-Money Era

• The Longevity Race

• The Great Retirement Crisis

Baked with love,

Anna Eisenberg ❤️